Inventiva S.A. (IVA)
Inventiva S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Daix, BF, FR. The stock last traded at $3.37, up 3.37% on the session, giving a market capitalisation of $175.2M. On trailing twelve-month figures it carries a trailing P/E of -1.50, a net margin of -7899.6%. Its beta of 0.91 implies it has historically moved less than the broad market.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Inventiva S.A. is most often compared with the following Healthcare names: